Functions of T cells were determined after intranasal and intratracheal immunization of mice with ovalbumin (Ova) and Bacillus firmus (Bf), a Gram-positive nonpathogenic bacterium of the external environment, or delipidated Bf (dBf) as adjuvants, with the aim to elucidate the mechanism of support of Ova-specific antibody production caused by Bf that had been observed in an identical experiment. Neither Bf nor dBf in a mixture with Ova stimulated Ova-specific T-cell response tested as antigen-specific blast transformation. By contrast, a mild polyclonal stimulation was observed in splenocytes from mice given dBf. In vitro incubation of splenocytes with 100 micrograms (but not 10 micrograms) of Bf or dBf led to a highly significant inhibition of proliferation below the control level in all groups of animals. Supernatants of splenocyte cultures were further tested for cytokine production. IL-10 and IFN-gamma were released after in vitro challenge with dBf and in some cases also with Bf. Analysis of sera demonstrated that administration of Ova + adjuvant brought about an increase in anti-Ova IgG1, IgG2a and IgG2b whereas treatment with Ova alone caused a rise in IgG1 only. The role of Bf or dBf in the enhancement of antigen-specific antibody production could be in influencing macrophages and inducing cytokine milieu composed of IL-10, IFN-gamma and other factors that leads to a bystander stimulation of specifically activated Ova-B cell receptor (Ova-BCR)-bearing cells.

Institute of Immunology and Microbiology 1st Faculty of Medicine Charles University 128 00 Prague Czechia

Zobrazit více v PubMed

J Exp Med. 1993 Oct 1;178(4):1309-20 PubMed

Folia Microbiol (Praha). 1992;37(6):455-60 PubMed

Immunology. 1992 May;76(1):72-8 PubMed

Infect Immun. 2000 Feb;68(2):672-9 PubMed

J Infect Dis. 1996 Mar;173(3):627-35 PubMed

Immunol Lett. 1998 Dec;64(2-3):161-6 PubMed

J Infect Dis. 2002 Nov 1;186(9):1261-9 PubMed

Immunology. 1996 Feb;87(2):250-8 PubMed

Infect Immun. 1982 Feb;35(2):523-7 PubMed

Int J Immunopharmacol. 1996 Dec;18(12):701-6 PubMed

Vet Immunol Immunopathol. 2003 Jan 10;91(1):1-12 PubMed

Infect Immun. 2000 Jun;68(6):3581-6 PubMed

Immunol Cell Biol. 1999 Oct;77(5):428-33 PubMed

J Exp Med. 1993 Feb 1;177(2):397-407 PubMed

J Immunol. 1999 Sep 1;163(5):2592-600 PubMed

J Exp Med. 1998 Dec 7;188(11):2019-31 PubMed

Infect Immun. 2001 Apr;69(4):2328-38 PubMed

Vaccine. 1992;10(2):75-88 PubMed

Infect Immun. 1999 Dec;67(12):6270-80 PubMed

Immunology. 1995 Jan;84(1):142-7 PubMed

J Exp Med. 1997 Apr 7;185(7):1203-10 PubMed

Folia Microbiol (Praha). 1994;39(6):501-4 PubMed

Folia Microbiol (Praha). 1995;40(4):413-6 PubMed

J Immunol. 2001 Feb 1;166(3):1471-81 PubMed

Cell Immunol. 2000 Dec 15;206(2):125-35 PubMed

Int J Immunopharmacol. 1993 Feb;15(2):87-92 PubMed

Eur J Immunol. 1991 Oct;21(10):2489-94 PubMed

Int J Immunopharmacol. 1998 Jul;20(7):359-68 PubMed

J Immunol. 1984 Jun;132(6):2736-41 PubMed

Folia Microbiol (Praha). 1995;40(6):647-51 PubMed

Folia Microbiol (Praha). 2002;47(2):193-7 PubMed

J Immunol. 2000 Mar 15;164(6):2937-46 PubMed

Immunol Lett. 2001 May 1;77(1):39-45 PubMed

Probiotics manipulate host cytokine response and induce antimicrobial peptides

Immunomodulatory effects of Bacillus firmus on mouse peritoneal cells in vitro

Adjuvant effect of Bacillus firmus in intranasal immunization of guinea pigs with inactivated type B infuenza virus

Intratracheal and intranasal immunization with ovalbumin conjugated with Bacillus firmus as a carrier in mice